- Home
- MNDR vs CANF Comparison
MNDR vs CANF Comparison
Compare MNDR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDR
- CANF
- Stock Information
- Founded
- MNDR 2016
- CANF 1994
- Country
- MNDR Singapore
- CANF Israel
- Employees
- MNDR N/A
- CANF N/A
- Industry
- MNDR
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MNDR
- CANF Health Care
- Exchange
- MNDR Nasdaq
- CANF Nasdaq
- Market Cap
- MNDR 9.3M
- CANF 9.6M
- IPO Year
- MNDR 2024
- CANF N/A
- Fundamental
- Price
- MNDR $1.90
- CANF $0.41
- Analyst Decision
- MNDR
- CANF Strong Buy
- Analyst Count
- MNDR 0
- CANF 3
- Target Price
- MNDR N/A
- CANF $10.50
- AVG Volume (30 Days)
- MNDR 32.5K
- CANF 234.5K
- Earning Date
- MNDR 10-31-2025
- CANF 11-27-2025
- Dividend Yield
- MNDR N/A
- CANF N/A
- EPS Growth
- MNDR N/A
- CANF N/A
- EPS
- MNDR N/A
- CANF N/A
- Revenue
- MNDR $7,646,739.00
- CANF $560,000.00
- Revenue This Year
- MNDR $608,852.40
- CANF $461.72
- Revenue Next Year
- MNDR N/A
- CANF N/A
- P/E Ratio
- MNDR N/A
- CANF N/A
- Revenue Growth
- MNDR N/A
- CANF N/A
- 52 Week Low
- MNDR $1.81
- CANF $0.41
- 52 Week High
- MNDR $40.00
- CANF $2.38
- Technical
- Relative Strength Index (RSI)
- MNDR 29.70
- CANF 24.47
- Support Level
- MNDR $1.93
- CANF $0.41
- Resistance Level
- MNDR $3.19
- CANF $0.43
- Average True Range (ATR)
- MNDR 0.19
- CANF 0.02
- MACD
- MNDR -0.16
- CANF -0.00
- Stochastic Oscillator
- MNDR 6.25
- CANF 5.29
About MNDR Mobile-health Network Solutions Class A Ordinary Shares
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).